RecruitingNCT06806917
Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
65 participants
Start Date
Dec 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous. In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques
Eligibility
Sex: MALE
Inclusion Criteria5
- Aged ≥ 18 years
- RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique
- Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique
- RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy
- Acquisition of informed consent
Exclusion Criteria2
- Patient with comorbidities with contraindication to surgery
- Hemorrhagic diathesis
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06806917
Related Trials
DESTINY-PANTUMOUR04
NCT0712400015 locations
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT0651561313 locations
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
NCT065936652 locations
Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
NCT068281851 location
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
NCT068669643 locations